DTacP
Phase 3Biologic
DTacP is one of 5 biologic programs targeting Diphtheria. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Diphtheria
#DrugCompanyPhaseTrials
1BCG Vaccine
GGynecologic Oncology Group
Phase 3
DTacP
CChangchun BCHT Biotechnology Co.
Phase 3
Tdap Vaccine
SanofiPhase 1
Pentavalent Vaccine
GSKPreclinical
PPV23
CanSino Biologics Inc.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diphtheria2 trials
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
Recruiting·IInstitute of Medical Biology, Chinese Academy of Medical Sciences·Phase 1·NCT06184542·460 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DTacP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- CChangchun BCHT Biotechnology Co.